---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-04-04T14:48:36.269774'
end_time: '2026-04-04T14:50:43.804892'
duration_seconds: 127.54
template_file: templates/drug_disease_research.md
template_variables:
  disease_name: brachydactyly type A1
  mondo_id: MONDO:0007215
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 51
---

## Question

# Drug-Disease Association Research Template

## Target Disease
- **Disease Name:** brachydactyly type A1
- **MONDO ID:** MONDO:0007215

## Research Objectives

Please provide a comprehensive research report on **drug therapies for brachydactyly type A1**.
Focus on approved treatments, investigational drugs, repurposing candidates, and off-label uses.

### Required Information

#### 1. Approved Drug Therapies
- What drugs are currently approved for this disease?
- Which regulatory agencies have approved them (FDA, EMA, PMDA, etc.)?
- What is the mechanism of action for each approved drug?

#### 2. Investigational and Pipeline Drugs
- What drugs are currently in clinical trials for this disease?
- What phase are they in (Phase I, II, III, IV)?
- What are the key clinical trial identifiers (NCT numbers)?

#### 3. Drug Repurposing Candidates
- Are there drugs approved for other indications that show promise for this disease?
- What evidence supports their potential use (case reports, off-label experience, preclinical data)?

#### 4. Contraindications
- Which drugs are contraindicated in patients with this disease?
- What is the mechanistic basis for contraindication?

#### 5. Adverse Events of Relevance
- Are there drugs known to cause or worsen this disease as an adverse effect?
- What is the frequency and severity of these adverse effects?

#### 6. Combination Therapies
- Are there established combination therapy regimens?
- What synergistic or additive effects are documented?

### Citation Requirements

- Cite primary literature (PMID preferred) for all claims
- Include clinical trial references (NCT numbers) where applicable
- Prioritize recent systematic reviews, meta-analyses, and landmark clinical trials
- Include direct quotes where possible to support key statements
- For regulatory approvals, reference the specific label or approval document

### Output Format

Structure your response as a narrative report with:
- Drug names (use generic/INN names)
- Disease-drug relationship type (indication, contraindication, adverse event, investigational)
- Evidence strength and source type (clinical trial, case report, regulatory label, etc.)
- PMIDs for all cited literature


## Output

# Drug Therapies for Brachydactyly Type A1: A Comprehensive Review of Approved, Investigational, and Repurposing Candidates

**Summary:** Brachydactyly type A1 (BDA1) is a rare autosomal dominant skeletal dysplasia characterized by shortening of middle phalanges, primarily caused by mutations in the Indian hedgehog (IHH) gene. Unlike achondroplasia and other skeletal dysplasias, **no pharmacological agents are currently FDA-approved specifically for the treatment of brachydactyly type A1**, as most cases do not require medical intervention. However, recent advances in understanding IHH and related signaling pathways, combined with emerging therapies for related skeletal dysplasias, present potential future therapeutic opportunities. This report synthesizes evidence regarding approved therapies, investigational agents, drug repurposing candidates, and mechanistic approaches for managing BDA1 and its associated complications, particularly when complicated by concurrent short stature or functional impairment.

## Historical Context and Epidemiology of Brachydactyly Type A1

Brachydactyly type A1 occupies a unique position in medical history as the first human condition described with clear Mendelian autosomal dominant inheritance[44]. The condition has been recognized for over a century, with clinical descriptions dating back to the early twentieth century. The genetic basis remained mysterious until 2001, when researchers identified heterozygous mutations in the Indian hedgehog gene (IHH) as the primary cause of BDA1[44]. This discovery represented a significant breakthrough in understanding skeletal development, as it demonstrated that disruption of the hedgehog signaling pathway could produce selective effects on digit development.

Epidemiologically, brachydactyly type A1 is classified as a rare disease, though exact prevalence estimates vary. More than 100 pedigrees have been reported worldwide according to clinical practice guidelines[2][2]. The condition exhibits remarkable consistency in inheritance patterns across diverse populations, suggesting a fundamental role of IHH mutations in digit development. Most individuals with BDA1 remain asymptomatic and unaware of their condition, presenting only when medical attention is sought for unrelated reasons or when family screening reveals the genetic change. The autosomal dominant inheritance pattern means that approximately fifty percent of offspring of affected individuals will inherit the condition, yet many remain undiagnosed due to the benign nature of the presentation.

The rarity of BDA1 as a disease requiring pharmacological intervention explains why no drug development programs have specifically targeted this condition. Unlike achondroplasia, which affects approximately one in 25,000 births and causes multiple systemic complications requiring medical management, BDA1 rarely produces functional disability or serious health consequences. Consequently, the pharmaceutical industry has not pursued drug development specifically for BDA1. Nevertheless, an understanding of potential therapeutic approaches is valuable for several reasons: first, to manage the subset of BDA1 patients who present with severe phenotypes; second, to address associated complications such as short stature when it occurs; and third, to provide insight into broader principles of skeletal dysplasia management that may inform future therapeutic development.

## Genetic Basis and Molecular Pathophysiology: Implications for Drug Development

Understanding the molecular basis of BDA1 is essential for rationally developing therapeutic approaches. The vast majority of BDA1 cases result from heterozygous mutations in the IHH gene, located on chromosome 2q35-q37[44][13]. The Indian hedgehog protein is a member of the hedgehog family of signaling molecules and plays crucial roles in endochondral bone formation. IHH is expressed in prehypertrophic and hypertrophic chondrocytes during bone development and regulates multiple processes essential for normal skeletal growth[32]. Recent mechanistic studies have clarified that IHH functions through three major pathways: regulation of chondrocyte differentiation through interaction with parathyroid hormone-related protein (PTHrP), promotion of chondrocyte proliferation, and specification of bone-forming osteoblasts[32][32].

The mutations in IHH that cause BDA1 predominantly localize to the amino-terminal signaling domain, affecting residues that are highly conserved across vertebrates[44]. Rather than producing complete loss of function, these mutations appear to cause subtle alterations in IHH signaling capacity and range of diffusion. Recent molecular studies have demonstrated that BDA1 mutations affect both signaling capacity and range due to impaired interactions with PTCH1 (the hedgehog receptor patched homolog 1) and HHIP (hedgehog interacting protein)[5]. A key finding from recent research is that in BDA1, high concentrations of IHH suppress apoptosis in developing joint interzones, preventing the programmed cell death necessary for proper joint cavitation[5]. This mechanistic insight opens therapeutic possibilities: manipulating apoptosis-related pathways or modulating IHH signaling intensity could potentially normalize joint development.

Alternative genetic causes of brachydactyly type A include mutations in BMPR1B (bone morphogenetic protein receptor type 1B), which causes brachydactyly type A2[37][10]. These mutations similarly affect skeletal development but through disruption of BMP signaling rather than hedgehog signaling. Some cases of severe brachydactyly involve mutations in GDF5 (growth differentiation factor 5), a BMP-family member crucial for digit formation[10]. These distinct genetic etiologies have important implications for drug development, as they suggest that different therapeutic approaches may be required depending on the specific genetic defect. Genotyping is therefore not merely an academic exercise but has potential therapeutic implications if targeted therapies become available.

## Current Standard of Care: Why Few Drugs Are Needed for Brachydactyly Type A1

Before discussing potential pharmacological interventions, it is important to establish why brachydactyly type A1 has not been a focus of drug development. The standard of care for uncomplicated BDA1 is conservative management because, in the vast majority of cases, the condition produces neither functional disability nor health complications[1]. Multiple sources confirm that no treatment is necessary for isolated brachydactyly type A1 in most patients[1][11][11]. The shortened fingers and toes do not impair grip strength, dexterity, or walking ability in typical cases. Individuals with BDA1 maintain normal employment, participate in sports, and report no quality-of-life decrements attributable to the digit shortening itself.

The condition becomes medically relevant only in specific circumstances. First, in severe cases where the shortened digits impair hand function or gait, physical therapy and orthotic devices may provide benefit[12]. Physical therapy aims to improve range of motion, strength, and proprioception of the affected digits, potentially compensating for anatomical limitations. Second, when BDA1 occurs in combination with other genetic conditions—such as Down syndrome or Cushing syndrome—medical management addresses the underlying systemic disorder rather than the brachydactyly specifically[1]. Third, when patients report cosmetic concerns affecting psychological well-being, plastic surgery may be considered, though this is purely elective and addresses appearance rather than function or health[1].

Fourth, and importantly for pharmacological consideration, when BDA1 occurs in association with short stature, growth-promoting therapy may be appropriate. Some patients with BDA1 carry IHH mutations that simultaneously affect skeletal growth, producing both short stature and digit shortening. In these cases, recombinant human growth hormone (rhGH) has demonstrated efficacy. A 2024 case report documented two siblings with short stature and non-classical BDA1 caused by a novel IHH mutation (c.387_388insC, p.Thr130Hisfs*18)[7]. Both siblings received rhGH therapy at 33 µg/kg/day for four years, achieving significant improvements in height with a height standard deviation score increase of +2.54 in the boy and +1.86 in the girl[7]. The paper emphasized that "rhGH showed promising effects" and recommended that clinicians "not overlook minor skeletal anomalies in patients with short stature, especially those with a family history," suggesting that growth hormone therapy represents a rational approach when short stature accompanies BDA1[7].

## Approved Drug Therapies Specifically for Brachydactyly Type A1

**There are no FDA-approved, EMA-approved, or otherwise internationally approved pharmacological agents specifically indicated for the treatment of brachydactyly type A1.** This statement reflects the clinical reality that BDA1, in its uncomplicated form, does not constitute a disease requiring pharmaceutical intervention. Regulatory agencies including the FDA, European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) have not approved any drugs with an indication that explicitly includes brachydactyly type A1.

This absence of approved therapies stands in sharp contrast to the situation for achondroplasia, the most common form of genetic dwarfism. Achondroplasia, caused by gain-of-function mutations in FGFR3, produces multiple serious complications including spinal cord compression, sleep apnea, and progressive neurological decline. In response to these clinical needs, two pharmaceutical agents have received FDA approval specifically for achondroplasia: vosoritide (VOXZOGO, approved December 2021) and navepegritide/TransCon CNP (YUVIWEL, approved February 2026)[28][27]. However, these approvals do not extend to brachydactyly type A1, as the underlying pathophysiologic mechanisms differ fundamentally. Achondroplasia results from FGFR3 gain-of-function and primarily involves dysregulation of endochondral ossification affecting long bone growth. BDA1 results from IHH pathway alterations that selectively affect middle phalanx development without producing the systemic skeletal dysplasia characteristic of achondroplasia.

Despite the absence of approved drugs specifically for BDA1, the regulatory approvals for achondroplasia therapies merit discussion because they illuminate potential future therapeutic directions for BDA1. These represent proof-of-concept that skeletal dysplasias caused by disrupted growth signaling can respond to pharmacological intervention.

## Investigational and Pipeline Therapies for Brachydactyly Type A1

### Growth Hormone Therapy as an Off-Label Investigational Approach

Recombinant human growth hormone (rhGH) represents the primary investigational pharmacological agent with documented clinical experience in BDA1, particularly when the condition is complicated by short stature. While growth hormone is not approved specifically for BDA1, the case report published in 2024 provides evidence that it merits consideration in selected patients[7]. The rationale for growth hormone therapy in BDA1 differs fundamentally from its traditional use in growth hormone deficiency or Turner syndrome. Rather, the IHH mutations that cause certain forms of BDA1 simultaneously disrupt both digit development and linear growth regulation, suggesting a more fundamental role of IHH in overall skeletal growth plate function.

The two siblings described in the 2024 case report received rhGH treatment at a dose of 33 µg/kg/day for four years[7]. Clinical outcomes were substantial: the male patient achieved a height standard deviation score (SDS) increase of +2.54, while the female achieved +2.11. Height velocity measurements improved significantly, accompanied by marked increases in insulin-like growth factor-1 (IGF-1) levels. Importantly, the report emphasized that "no noticeable adverse effect was observed during this treatment," suggesting that rhGH was well-tolerated[7]. These findings represent a departure from the historical consensus that brachydactyly type A1 required no treatment, suggesting that selected patients with concurrent growth impairment merit evaluation for growth hormone therapy.

The authors concluded that "the therapy of rhGH showed promising effects" and recommended that "clinicians should not overlook minor skeletal anomalies in patients with short stature, especially those with a family history" to avoid misdiagnosis as idiopathic short stature (ISS) or growth hormone deficiency (GHD)[7]. This recommendation has important implications: it suggests that genetic testing should be considered in short stature patients with subtle skeletal findings consistent with brachydactyly, as specific etiologic diagnosis could modify treatment approaches. The case supports the potential for rhGH to address growth impairment in BDA1, though this remains an off-label use not formally approved for this indication.

A separate study examining growth hormone treatment in short stature homeobox-containing gene deficiency (SHOX-D) provides relevant comparator data[39]. In a randomized, controlled, multicenter trial, 52 prepubertal subjects with SHOX-D received either rhGH at typical doses or placebo for two years[39]. The GH-treated group achieved significantly greater first-year height velocity (8.7 ± 0.3 cm/yr vs. 5.2 ± 0.2 cm/yr, P < 0.001) and second-year height velocity (7.3 ± 0.2 vs. 5.4 ± 0.2 cm/yr, P < 0.001) compared to untreated controls, with final height gains of 16.4 ± 0.4 cm versus 10.5 ± 0.4 cm in year two[39]. These results from a related genetic skeletal dysplasia demonstrate that growth hormone can produce substantial improvements in growth when short stature results from specific gene defects affecting skeletal development. The mechanism likely involves IGF-1–mediated stimulation of growth plate chondrocytes and may be particularly effective in conditions where baseline growth plate function is suboptimal due to genetic dysregulation.

### Emerging Approaches Targeting IHH Signaling

While no IHH-targeted drugs have entered clinical trials specifically for BDA1, recent advances in understanding IHH signaling have revealed multiple potential therapeutic targets. Studies of BDA1 pathogenesis have identified that abnormal apoptosis regulation in developing joints contributes to the phenotype[5]. Specifically, mutations in IHH that cause BDA1 suppress apoptosis in joint interzones, preventing the cell death necessary for joint cavitation. This mechanistic insight suggests that apoptosis-inducing agents or drugs that modulate the IHH-dependent apoptotic pathway could potentially prevent BDA1 phenotypes during fetal development.

A 2024 study demonstrated that overexpression of GAS1 (growth arrest-specific 1), a gene involved in IHH signaling, rescued the BDA1 phenotype in mice, allowing progression to cavitation and joint formation[5]. The study further showed that the balance between CDON (cell adhesion molecule-related/downregulated by oncogenes) and GAS1 expression is crucial for regulating apoptosis in developing joints[5]. These findings suggest that modulation of this balance through pharmacological or genetic approaches could ameliorate BDA1. Future drugs targeting this pathway might enhance GAS1 function or inhibit CDON in the developing joint interzone, potentially preventing joint fusion abnormalities characteristic of BDA1.

The hedgehog signaling pathway includes multiple therapeutic nodes. Smoothened (SMO) agonists and antagonists have been developed for other diseases, including basal cell carcinoma[19]. Vismodegib and sonidegib are hedgehog pathway inhibitors that have received FDA approval for advanced basal cell carcinoma but are not used for skeletal dysplasias due to their adverse effect profile[19]. These drugs produce significant toxicities including muscle spasms, altered taste perception (ageusia/dysgeusia), alopecia, and weight loss, primarily through inhibition of hedgehog signaling in multiple tissues[19]. While hedgehog pathway inhibition is not appropriate for treating BDA1, understanding the pleiotropic effects of hedgehog manipulation illustrates that any IHH-targeted therapy for BDA1 would require tissue-specific or developmental stage-specific delivery to avoid off-target effects.

## Drug Repurposing Candidates: Related Skeletal Dysplasia Therapies

### Vosoritide (VOXZOGO): C-Type Natriuretic Peptide Analog for Achondroplasia

Vosoritide (C-type natriuretic peptide, CNP) represents an approved therapy for achondroplasia that merits discussion as a potential repurposing candidate for brachydactyly type A1, though with important caveats regarding mechanistic applicability. Vosoritide received FDA accelerated approval in December 2021 for treatment of achondroplasia in children aged five years and older with open epiphyses[28][18]. The mechanism of action involves binding to natriuretic peptide receptor-B (NPR-B), which reduces FGFR3 activity and stimulates bone growth[28]. In a phase 3 randomized, double-blind, placebo-controlled trial, vosoritide recipients grew an average of 1.57 centimeters more than placebo recipients, measured as annualized growth velocity[28].

Why might vosoritide theoretically apply to BDA1? Both achondroplasia and certain forms of BDA1 result in disproportionate skeletal dysplasia, though through different mechanisms. Additionally, both conditions can be complicated by growth impairment. However, the fundamental differences in pathophysiology limit the applicability of vosoritide to BDA1. Vosoritide specifically antagonizes FGFR3 signaling, which is dysregulated in achondroplasia but not directly implicated in BDA1 pathogenesis. BDA1 results from IHH pathway disruption, not FGFR3 dysregulation. Therefore, while vosoritide might address growth velocity in a BDA1 patient with concurrent achondroplasia or FGFR3 dysregulation, it would not directly target the underlying BDA1 pathology.

Nevertheless, the approval of vosoritide establishes proof-of-concept that skeletal dysplasias can be pharmacologically treated, providing regulatory pathway precedent for future BDA1 therapies. The accelerated approval pathway used for vosoritide, based on annualized growth velocity as a surrogate endpoint, establishes a regulatory framework that could potentially be adapted for IHH-targeted therapies if similar growth-promoting effects were demonstrated in BDA1 patients with concurrent short stature.

### Navepegritide (YUVIWEL): Once-Weekly C-Type Natriuretic Peptide Analog

Navepegritide (YUVIWEL) represents the most recent pharmacological advance for achondroplasia, receiving FDA approval on February 27, 2026[27]. This therapy is notable as the first once-weekly treatment for achondroplasia, employing the TransCon technology platform to provide continuous exposure to C-type natriuretic peptide. Like vosoritide, navepegritide antagonizes FGFR3 signaling and is not mechanistically targeted at IHH pathways relevant to BDA1. However, the regulatory approval of a once-weekly formulation represents an important advance in treatment convenience and potentially improves therapeutic adherence.

The clinical package for navepegritide included data from three randomized, double-blind, placebo-controlled clinical trials with up to three years of open-label extension data[27]. The pivotal ApproaCH Trial demonstrated efficacy and excellent tolerability. As with vosoritide, the most common adverse effects include injection site reactions, decreased blood pressure, and gastrointestinal symptoms[27]. The approval of navepegritide further establishes that systemic approaches to skeletal dysplasia treatment through growth-regulating pathways can achieve regulatory approval and clinical benefit. For BDA1 patients with concurrent achondroplasia or FGFR3 dysregulation, navepegritide might provide therapeutic benefit; however, it does not address isolated BDA1 pathology.

### Infigratinib: FGFR Selective Tyrosine Kinase Inhibitor

Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor currently in development for achondroplasia and hypochondroplasia[14][14]. While primarily targeting FGFR3-driven skeletal dysplasias rather than IHH-driven BDA1, infigratinib represents another example of pharmacological progress in treating rare skeletal disorders. Recent data (2025) demonstrate that infigratinib shows promise for hypochondroplasia, a condition similar in pathophysiology to achondroplasia[14]. In cellular models and mouse models of hypochondroplasia, infigratinib demonstrated potent FGFR3 inhibitory effects and significant improvement in skeletal growth[14]. These preclinical findings supported advancement toward clinical trials in hypochondroplasia, expanding the therapeutic paradigm beyond achondroplasia.

### TYRA-300: FGFR3-Selective Kinase Inhibitor

TYRA-300 represents another investigational FGFR3-selective kinase inhibitor that has demonstrated efficacy in preclinical models of both achondroplasia and hypochondroplasia[6][49]. Preclinical studies revealed that TYRA-300 treatment increased bone length in mouse models of both conditions, with average normalization of long bone length toward wild-type of approximately 25-26 percent in both models[6]. Additionally, TYRA-300 increased the area of the foramen magnum in achondroplasia mice by 25.17 percent compared with vehicle-treated controls, potentially reducing risk of neurological complications from foramen magnum stenosis[6].

## Contraindicated Drugs and Teratogenic Considerations

An important aspect of managing brachydactyly type A1, particularly from a therapeutic standpoint, relates to drugs that are contraindicated or that can cause or exacerbate skeletal malformations. This consideration is especially relevant for BDA1 because it is an autosomal dominant inherited condition, and individuals with BDA1 who become pregnant may be concerned about passing the condition to offspring or about exposing offspring to additional teratogenic risks.

### Antiepileptic Drugs and Skeletal Teratogenicity

Multiple antiepileptic drugs (AEDs) have well-established teratogenic effects that include skeletal abnormalities including shortening of digits. Phenytoin, in particular, causes fetal hydantoin syndrome (FHS) when exposure occurs *in utero*, producing multiple dysmorphic findings including distal digital hypoplasia (shortening of distal phalanges)[21]. A recent study showed an 11 percent prevalence of FHS in children exposed to phenytoin *in utero*, with 30 percent of exposed children expressing at least some features of FHS[21]. Valproic acid presents an even higher risk, with a congenital malformation rate of 6.2 percent, approximately triple the rate of unexposed pregnancies[21].

Topiramate carries a specific risk of oral clefts at 11-fold higher rate in fetuses compared to unexposed pregnancies[21]. Carbamazepine, lamotrigine, and gabapentin all carry teratogenic risks, though generally lower than phenytoin or valproate[21]. These drugs, if used in pregnant individuals with BDA1, could theoretically exacerbate skeletal dysplasia or produce additional digit abnormalities through mechanisms distinct from the genetic IHH mutation. Pregnancy registries and clinical guidelines recommend careful risk-benefit assessment when AEDs are necessary during pregnancy, potentially switching to medications with lower teratogenic potential when feasible.

### Retinoic Acid and Vitamin A Excess

Vitamin A excess during pregnancy carries well-characterized teratogenic risks including skeletal abnormalities, central nervous system malformations, and craniofacial abnormalities[43]. Isotretinoin (Accutane), a retinoid used for severe acne, is highly teratogenic and absolutely contraindicated in pregnancy, producing multiple skeletal and craniofacial anomalies. All-trans retinoic acid (ATRA) and other retinoids similarly carry significant teratogenic potential. The mechanism involves disruption of retinoid signaling during critical windows of skeletal development. Both excessive and deficient vitamin A during pregnancy can produce adverse fetal effects, though for different reasons[43]. These considerations suggest that pregnant individuals with BDA1 should maintain recommended vitamin A levels but avoid supplementation beyond physiologic requirements, particularly avoiding retinoid medications.

Recent research has clarified the paradoxical teratogenic mechanism of excess retinoic acid[20]. High-dose retinoic acid exposure triggers upregulation of catabolizing enzymes (CYP26A1 and CYP26B1) and downregulation of synthesizing enzymes (RALDH family), resulting in prolonged local retinoic acid deficiency that produces developmental abnormalities[20]. This mechanism explains why both excess and deficiency produce similar malformations: the ultimate problem is abnormal retinoic acid signaling. For individuals with BDA1, avoiding retinoic acid medications and maintaining normal vitamin A intake represents straightforward contraindication guidance.

### Hedgehog Pathway Inhibitors

Vismodegib and sonidegib, the approved hedgehog pathway inhibitors for basal cell carcinoma, are theoretically contraindicated in individuals with BDA1 given that hedgehog pathway disruption is central to BDA1 pathogenesis[19]. While no direct evidence documents worsening of BDA1 with these drugs, the mechanism of action—inhibiting hedgehog signaling—could exacerbate the underlying IHH pathway dysfunction in BDA1 patients. Additionally, hedgehog pathway inhibitors carry significant toxicities including muscle spasms and altered taste perception, making them inappropriate for chronic use even in conditions where hedgehog pathway inhibition is therapeutically beneficial.

## Adverse Events of Relevance: Drugs That Can Cause Skeletal Malformations

### Maternal Medication-Related Brachydactyly

A comprehensive examination of adverse drug reaction databases revealed reports of congenital hand malformations including potential brachydactyly associated with maternal medication use during pregnancy[42]. However, in a 2024 analysis of spontaneous adverse drug reaction reporting, only five cases of congenital hand malformation (ICD-10: DQ681) were identified, with 13 different drugs reported across these five cases[42]. No drug was reported more than once, leading the researchers to conclude that "no clear evidence of teratogenic effects was found" for a specific drug-brachydactyly association[42]. This finding is reassuring and suggests that most medications do not carry substantial risk of producing brachydactyly.

However, the rarity of signal detection also reflects the methodological challenges in detecting rare adverse effects through spontaneous reporting systems. The authors noted that if a hypothetical new drug increased the risk of a specific congenital malformation by 20 percent, it would need to be used by at least 500 pregnant women before the increase would achieve statistical significance[42]. This illustrates why many teratogenic effects of medications remain underrecognized, particularly for rare malformations like brachydactyly.

## Current Management Approaches: Supporting Evidence for Non-Pharmacological Interventions

Given the absence of approved pharmacological therapies specifically for BDA1, current management focuses on non-pharmacological approaches including physical therapy, orthotic devices, and surgical intervention in severe cases. These supportive measures merit discussion as they represent the evidence-based standard of care and provide context for understanding when pharmacological intervention might be appropriate.

### Physical Therapy and Functional Optimization

Physical therapy represents a cornerstone of management for BDA1 patients with functional impairment[12][47]. The goal of physical therapy is to optimize strength, coordination, and range of motion of the affected digits through progressive resistance exercises and functional training. For individuals with significant digit shortening affecting grip strength or fine motor control, physical therapy can enhance compensatory strategies, allowing improved hand function despite anatomical limitations.

A comprehensive review of skeletal dysplasia management emphasized that physical therapy can improve muscle strength, coordination, and range of motion, with stronger muscles potentially compensating for bony differences and protecting joints[47]. For BDA1 specifically, strengthening of intrinsic hand muscles and optimization of proprioceptive feedback can maximize functional capacity despite shortened middle phalanges. The timing and intensity of physical therapy should be individualized based on the severity of digit shortening and the degree of functional limitation reported by the patient.

### Orthotic Devices and Adaptive Equipment

Custom orthotic devices can provide external support and potentially prevent progressive deformity in BDA1 patients with functional limitations[12][47]. For individuals with specific functional deficits—such as difficulty gripping cylindrical objects or maintaining precise finger positioning—occupational therapists can design custom hand orthoses that distribute loads across the shortened digits and potentially enhance function. While orthoses do not correct the underlying anatomical abnormality, they can provide practical functional benefits and improve quality of life.

### Surgical Intervention: Distraction Osteogenesis and Surgical Lengthening

In rare cases of severe brachydactyly significantly impairing function or causing substantial cosmetic distress, surgical lengthening procedures may be considered[1][30]. Distraction osteogenesis represents a bone-lengthening technique that has been successfully applied to brachydactyly. A 2023 case report described a 55-year-old patient with congenital brachytelephalangy (shortening of distal phalanges, a related condition) who underwent distraction osteogenesis using the Ilizarov minifixator[30]. The distal phalanx was carefully osteotomized and gradually lengthened over months, achieving 5 mm of lengthening without adverse events and resulting in improved cosmetic appearance of the thumb[30].

The distraction osteogenesis approach exploits the physiologic phenomenon of callus formation during bone healing. By slowly separating the osteotomized bone fragments—typically at rates of 1 mm per day—new bone forms in the gap, gradually lengthening the digit. This technique is less invasive than classical osteotomy and can be managed by the patient at home using external fixation devices. The success of distraction osteogenesis in related brachydactyly variants suggests potential applicability to BDA1, though it remains reserved for severe cases given the surgical risks and the benign natural history of uncomplicated BDA1.

## Combination Therapies and Emerging Approaches

### Synergistic Pathway Modulation for Skeletal Dysplasia

Recent research has suggested that targeting multiple skeletal signaling pathways simultaneously may produce greater therapeutic effects than single-pathway modulation. In particular, the interaction between IHH, BMP, and Wnt signaling in skeletal development presents opportunities for combination therapy[46]. A study examining brachydactyly type B mutations in the BMP antagonist Noggin demonstrated genetic interaction between Noggin and Ror2, a receptor in the non-canonical Wnt pathway[46]. The findings suggested that Noggin can sensitize cells to Wnt/PCP pathway activation mediated by ROR2, providing evidence for cross-talk between BMP and Wnt signaling in skeletal development[46].

These mechanistic insights raise the possibility that future pharmacological approaches to skeletal dysplasia might involve combination therapies targeting multiple pathways. For BDA1 specifically, the interaction between IHH signaling and BMP or Wnt pathways could represent therapeutic targets. However, such combination approaches remain entirely theoretical for BDA1 and have not been tested clinically. The complexity of skeletal signaling networks and the potential for off-target effects would require careful preclinical validation before clinical application.

### Growth Hormone and Pathway-Targeted Combination

While not yet clinically tested, the potential combination of growth hormone with IHH-pathway modulators merits theoretical consideration. The case report of BDA1 patients responding to rhGH therapy suggests that general growth promotion can be beneficial for BDA1 patients with concurrent short stature[7]. Future therapeutic approaches might combine IGF-1 signaling augmentation (through rhGH) with specific IHH-pathway enhancement to address both overall growth impairment and specific digit development abnormalities. However, this remains speculative pending development of effective IHH-targeted therapies and clinical investigation of combination approaches.

## Regulatory Pathways and Future Therapeutic Development

### Rare Pediatric Disease Priority Review Voucher

The approval of navepegritide for achondroplasia involved granting of a Rare Pediatric Disease Priority Review Voucher, a regulatory incentive designed to encourage development of therapies for rare pediatric diseases[27]. This regulatory pathway could potentially accelerate development of BDA1 therapies if pharmacological approaches proved effective in clinical trials. Understanding these regulatory incentives is important for understanding future drug development trajectory for rare skeletal dysplasias.

### Accelerated Approval Pathway

Both vosoritide and navepegritide received FDA approval through the accelerated approval pathway, based on surrogate endpoints (annualized growth velocity) rather than clinical outcomes[28][27]. This pathway allows approval of drugs that treat serious conditions or address unmet medical needs based on surrogate markers expected to predict clinical benefit, with contingency that confirmatory trials demonstrate ultimate clinical benefit. For BDA1, if a drug demonstrated improvement in middle phalanx development on radiographic imaging in clinical trials—a surrogate for functional improvement—the accelerated approval pathway could potentially enable faster approval, conditional on subsequent demonstration of functional benefit.

## Challenges in Drug Development for Brachydactyly Type A1

Several factors explain why pharmaceutical development for BDA1 has not advanced despite understanding of its molecular basis. First, the condition is benign in most cases, eliminating market incentive for industry investment. Unlike achondroplasia, which causes multiple serious complications requiring medical management, typical BDA1 produces cosmetic concerns without functional or health consequences. This limited disease burden reduces both medical need justification and commercial viability for drug development.

Second, BDA1 phenotypes primarily manifest during fetal development. The opportunity to prevent or reverse BDA1 would require intervention during pregnancy, raising complex regulatory and ethical questions regarding fetal pharmacotherapy. Most development programs would face insurmountable barriers to clinical trial design and regulatory approval for drugs administered during pregnancy.

Third, the benign natural history of BDA1 means that observational or historical control comparison would be difficult in clinical trials. Demonstrating that a drug improved middle phalanx development would require radiographic comparison in clinical trial participants versus matched controls—a standard unmet in rare disease contexts.

## Mechanism-Based Therapeutic Strategies: Future Directions

### IHH Pathway Enhancement Approaches

Future pharmacological approaches to BDA1 might involve enhancement of IHH signaling or restoration of normal IHH-dependent signaling. Since BDA1-associated IHH mutations produce subtle changes in signaling capacity and range, potential therapeutic approaches could include compounds that enhance remaining IHH function through receptor amplification, increased translational efficiency of mutant IHH protein, or enhancement of downstream signaling components.

### Apoptosis Pathway Modulation

Recent mechanistic insights regarding apoptosis dysregulation in BDA1 joint interzones suggest that future therapies might enhance apoptosis during critical developmental windows[5]. GAS1 overexpression rescued the BDA1 phenotype in mice, allowing normal joint formation[5]. This suggests that drugs enhancing GAS1 function or inhibiting CDON in developing joint interzones could prevent the characteristic joint fusion abnormalities of BDA1.

### Gene Therapy Approaches

While beyond the scope of current pharmacological interventions, gene therapy targeting IHH mutations represents a potential long-term therapeutic approach. CRISPR-based correction of IHH mutations, mRNA replacement therapy, or in utero gene delivery could theoretically normalize digit development in BDA1. However, these approaches remain experimental and face substantial regulatory and technical barriers.

## Conclusion: Synthesis of Evidence and Future Directions

Brachydactyly type A1 represents a unique challenge in pharmacological medicine: a well-characterized genetic disorder for which no approved drugs exist and for which the clinical need for pharmacological intervention remains limited. The absence of FDA-approved drugs specifically for BDA1 does not reflect lack of scientific understanding or regulatory pathway uncertainty; rather, it reflects the benign natural history of uncomplicated BDA1 and the consequent lack of market incentive for pharmaceutical development.

However, recent advances in understanding IHH signaling mechanisms, combined with emerging therapeutic successes in related skeletal dysplasias like achondroplasia, create a foundation for future pharmacological approaches to BDA1. The case report demonstrating efficacy of recombinant human growth hormone in BDA1 patients with concurrent short stature establishes that pharmacological intervention is both feasible and potentially beneficial in selected clinical contexts. Mechanistic insights regarding apoptosis dysregulation in BDA1 joint development suggest future therapeutic targets. The regulatory precedents established by accelerated approvals of achondroplasia therapies demonstrate that rare skeletal dysplasias can receive regulatory approval based on appropriate surrogate endpoints.

For the subset of BDA1 patients who present with functional impairment or significant short stature, current evidence supports consideration of physical therapy, orthotic devices, and in carefully selected cases, growth hormone therapy for those with documented growth hormone deficiency or growth impairment. Surgical approaches including distraction osteogenesis remain available for severe cases where functional or cosmetic impairment is substantial. Future pharmacological development should focus on IHH-pathway-targeted therapies aimed at enhancing joint development and overall skeletal growth in BDA1 patients.

Until such therapies are developed and clinically validated, the standard of care for uncomplicated BDA1 remains reassurance, genetic counseling for family planning purposes, and surveillance for associated complications. For clinicians encountering BDA1 patients with concurrent short stature, careful consideration of growth hormone evaluation is warranted, recognizing the emerging evidence that growth promotion may address both stature and skeletal dysplasia aspects of the condition.